Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?

Related Articles

Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?

Future Oncol. 2018 Apr 27;:

Authors: Tampellini M, Bironzo P, Di Maio M, Scagliotti GV

Abstract
5-Fluorouracil- and leucovorin-based chemotherapy regimens are the backbone of colorectal cancer treatment. The addition of oxaliplatin, irinotecan and monoclonal antibodies to this backbone has largely improved clinical outcomes, but has also led to new questions, with conflicting data frequently reported in studies. Thymidine phosphorylase (TP) is a nucleoside-metabolizing enzyme involved in 5-fluorouracil pharmacokinetics, as well as inflammatory responses, neoangiogenesis and apoptosis. TP expression is regulated by hypoxia, inflammatory cytokines and antitumoral agents. We hypothesize that TP could be the unforeseen driver in the conflicting data observed with different regimens commonly used in colorectal cancer treatment. Greater comprehension of the role of this enzyme in tumor progression and pyrimidine metabolism may lead to more accurate, patient-tailored therapy.

PMID: 29701074 [PubMed - as supplied by publisher]

https://ift.tt/2HwVWpM